A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
University of Pittsburgh
National Institutes of Health Clinical Center (CC)
Bicara Therapeutics
Brigham and Women's Hospital
Ruijin Hospital
VM Oncology, LLC
University of Texas Southwestern Medical Center
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello